Another aspect of CAR activation and development of NAFLD is the effect of CAR on adiponectin, an adipocyte hormone, and on the PPARα signaling pathway as indicated by pathway analysis of our transcriptome data in normal and hyperlipidemic liver. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.